Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Dow
McKesson
Baxter
McKinsey

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Tasquinimod

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Tasquinimod: Sponsors, patents, clinical trial progress

Tasquinimod is an investigational drug.

There have been 9 clinical trials for Tasquinimod. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Carcinoma, and Stomach Neoplasms. The leading clinical trial sponsors are Active Biotech AB, Ipsen, and Sidney Kimmel Comprehensive Cancer Center.

There are eleven US patents protecting this investigational drug and one hundred and one international patents.

Recent Clinical Trials for Tasquinimod
TitleSponsorPhase
A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate CancerSidney Kimmel Comprehensive Cancer CenterPhase 1
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate CancerActive Biotech ABPhase 2
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate CancerNational Cancer Institute (NCI)Phase 2

See all Tasquinimod clinical trials

Clinical Trial Summary for Tasquinimod

Top disease conditions for Tasquinimod
Top clinical trial sponsors for Tasquinimod

See all Tasquinimod clinical trials

US Patents for Tasquinimod

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tasquinimod   See Pricing Quinoline carboxamides for use in the treatment of leukemia ACTIVE BIOTECH AB (Lund, SE)   See Pricing
Tasquinimod   See Pricing Quinoline carboxamides for use in the treatment of multiple myeloma Active Biotech AB (Lund, SE)   See Pricing
Tasquinimod   See Pricing Quinoline derivatives Active Biotech AB (Lund, SE)   See Pricing
Tasquinimod   See Pricing Drugs for the treatment of malignant tumors Active Biotech AB (Lund, SE)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tasquinimod

Drugname Country Document Number Estimated Expiration Related US Patent
Tasquinimod Australia 2015348778 2034-11-19   See Pricing
Tasquinimod Brazil 112017009854 2034-11-19   See Pricing
Tasquinimod Canada 2967112 2034-11-19   See Pricing
Tasquinimod China 107072989 2034-11-19   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Express Scripts
Medtronic
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.